NCT03206931
No Longer Available
Not Applicable
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.
ConditionsSolid Tumors Harboring NTRK Fusion
Overview
- Phase
- Not Applicable
- Status
- No Longer Available
- Sponsor
- Bayer
Overview
Brief Summary
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 1 Month to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
- •Previous treatment with a kinase inhibitor with known activity on TRK inhibition
- •Unable to participate in an ongoing selitrectinib clinical trial
- •Medically suitable for treatment with selitrectinib
Exclusion Criteria
- •Currently enrolled in an ongoing clinical study with a TRK inhibitor
Investigators
Similar Trials
No Longer Available
Not Applicable
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) MutationsNCT03409081Astellas Pharma Global Development, Inc.
Unknown
Not Applicable
Expanded Access Use of Cemiplimab in Patients With Solid TumorsNCT06132191Regeneron Pharmaceuticals
No Longer Available
Not Applicable
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene FusionsCancers With NTRK, ROS1, or ALK Gene FusionsNCT03066661Hoffmann-La Roche
Approved For Marketing
Not Applicable
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationNon Small Cell Lung CancerMedullary Thyroid CancerColon CancerBreast CancerPancreatic CancerPapillary Thyroid CancerOther Solid Tumors With Evidence of Activating RET AlterationNCT03906331Eli Lilly and Company
Available
Not Applicable
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesPancreatic CancerSmall Bowel CancerColorectal CancerMelanomaNon Small Cell Lung CancerThyroid CancerBladder CancerHead and Neck CancerGastric CancerEsophageal CancerCholangiocarcinomaOvarian CancerHepatocellular CarcinomaGlioblastomaMAPK Gene MutationKRAS Activating MutationBRAF Gene MutationNRAS Gene MutationHRAS Gene MutationMEK MutationERK MutationNCT04566393xCures